EFFECTIVE PATIENT TRAINING AND ONBOARDING FOR WEARABLE INJECTION DEVICES
According to a recent survey conducted by the University of Texas Medical Branch at Galveston (UTMB), correct auto-injector use, treating anaphylaxis can be as low as 22%, and up to 92% of asthmatic patients incorrectly use their inhalers. These rates are often no better for devices that are used daily. It comes down to ineffective patient training and on-boarding. This might only get worse as today's biologics look to reduce dose frequency to twice, even once monthly and utilize more complex 'on-body' injection systems.
These therapies, including new combination products and self-administrated drug delivery devices can present different usability challenges with their unique use sequences and intricacies.
We will discuss how the holistic design of a multi-sensory based device training program can help ensure proper device use, even in light of reduced dose frequency or device complexity. We'll reinforce that device usability, of course, relies on the application of a solid HF philosophy and methodology. However, this is not only for engineering and design development. By applying the same HF principles to the IFU, onboarding, training device, educational materials and packaging, it can help reduce use errors, anxiety, and establish muscle memory, en route to improved patient outcomes.
Participants will walk away with learnings regarding the development of effective training packages for the next generation of self-administration combination products.
Strategies, tools and techniques:
How to provide patients with the proper drug administration education during the onboarding phase to help minimize device use errors
How to apply good HF principles to aspects of drug-delivery beyond just the development of the device itself
How to combat improper drug delivery during selfadministration with multisensory training devices to maximize learning retention
Chris Evans, VP of Research & Innovation, West Pharmaceutical Services BIOPHARMA REQUIREMENTS AND OPPORTUNITIES FOR PLATFORM-BASED WEARABLE INJECTION SYSTEMS
Many biopharma companies have large portfolios of injectable therapies with large dose volumes or extended delivery periods that are suitable for use with wearable injection systems. To ensure that each wearable device is simple to customize, commercialize and use with a target therapy or indication, platform-based technologies are increasingly being utilized by a multitude of biopharma companies.
A range of criteria are commonly utilized in the selection of a preferred technology platform and partner.
Ian Hanson, Senior Vice President and General Manager for Wearable Injectors and Patch Pump Technologies,Unilife Intelligent Subcutaneous Delivery: Moving Beyond the Bolus
With an increasing number of injectable drugs and biologics coming to market, the industry is looking for innovative technology that can simplify delivery, offering improved patient adherence and increasing clinical efficiencies. Conventional methods of injection, such as syringes and pens, provide answers for simple bolus injectable delivery.
Advances in intelligent subcutaneous delivery can help address the problems of complex dosing regimens, including interval and continuous infusion.
Key takeaways:
Route of administration is a key consideration during pharmaceutical development
Conventional methods have limitations, restricting the growth of subcutaneously delivered drugs
Complex, intelligent subcutaneous delivery opens new doors in the drug development landscape
Michael Graffeo, VP Business Development, Delivery Systems, Insulet The New Frontier: Advancing the Quality and Functionality of Drug Delivery with Ion-Exchanged Glass Strengthened Prefillable Syringes
Maggie Tsai, Product Manager, BD Medical, Pharmaceutical Systems Some things are Worth the Wait: Targeted Drug Delivery with the World's First Medical Grade Carbon Nanotubes
Data will be presented demonstrating:
In vivo toxicity testing shows our medical grade carbon nanotubes (MGMR®) are safe
Efficient loading of small and large molecule drugs
Covalent and non-covalent binding of targeting proteins and peptides for targeted delivery of the drug payload
Controlled/extended release
Application of the technology in oncology and other therapeutic areas
Commercial-scale manufacturing capability
Kent Phelps, Co founder & CEO, Bio-pact
UNS Price at posting:
12.5¢ Sentiment: Hold Disclosure: Held
